DNA Testing Helps Match Mental Health Medications to Patients

For people with depression, anxiety, or co-occurring mental health and addiction disorders, finding the right mental health medications has long meant enduring months of frustrating trial and error. A growing technology called pharmacogenomic testing can change this by using a simple DNA cheek swab to help clinicians prescribe smarter from the start.

What is Pharmacogenomic Testing?

Pharmacogenomic testing analyzes how your genes may affect medication outcomes by examining clinically important genetic variations in your DNA. The results give prescribers insight into how a patient may metabolize or otherwise respond to psychiatric medications. 

Tests like GeneSight Psychotropic cover more than 60 commonly prescribed mental health medications and provide information about which drugs may require dose adjustments, have a less likely chance to work, or carry an increased risk of side effects based on a patient’s genetic profile.

The test itself is straightforward. Undergo a cheek swab in a provider’s office or at home, and results typically arrive within a few days. Participants see the potential medications categorized into different response tiers.

Why It Matters for Mental Health Treatment

Dozens of medications out there can treat depression and other mental illnesses. Selecting the right one is an often challenging and frustrating process. Pharmacogenomic testing enables clinicians to identify and avoid medications unlikely to work or may cause side effects for a specific patient. 

That matters enormously for people in behavioral health treatment, especially those dealing with dual diagnoses, where a mental health condition and a substance use disorder co-exist. For instance, veterans often have dual diagnoses as they battle trauma and cope with addictions. When someone’s already navigating the complexities of 2+ disorders, spending months adjusting ineffective antidepressants or mood stabilizers can derail recovery entirely.

The test looks at how organs process medicine at a genetic level and how medication is processed by the brain’s receptors and transporters that control mood, focus and anxiety. Patients using GeneSight-guided prescribing have shown 50% greater symptom improvement and fewer medication changes compared to standard treatment approaches.

Mental Health Medications & Dual Diagnoses

Integrated behavioral health treatment that addresses dual diagnoses produces better outcomes than treating each one in isolation. Getting mental health medications right is a cornerstone of that integrated care.

Pharmacogenomic testing can guide care for co-occurring conditions not only at the start of treatment but also when evaluating whether current medications are the right fit. For someone in residential treatment for addiction who’s also managing major depression or anxiety, knowing that a prescribed antidepressant is genetically unlikely to be effective before weeks of failed trials can make the difference between staying in recovery and relapsing.

Clinical Evidence & Limitations

The research supporting pharmacogenomic testing continues to evolve. Nevertheless, clinicians and patients should understand the limitations. For instance, the tests also don’t predict which medication will definitively work.

Pharmacogenomics isn’t part of formal clinical practice guidelines for mental health, so doctors have no established standard on who should be tested or at what stage. Eligible candidates should make a decision after consulting their healthcare provider. 

Choosing medications based on health history and symptoms should remain the standard initial approach. Patients who’ve had difficulty finding an effective option or have experienced intolerable side effects after multiple drug trials can find genetic testing useful.

People seeking mental health treatment also have concerns over costs. Medicare Part B covers pharmacogenomic testing when ordered by a treating physician for patients being prescribed or considering psychiatric medications, so beneficiaries often have no out-of-pocket cost. Medicaid may also cover the full cost depending on the state and the patient’s clinical situation, and Medicare Advantage and commercial plans may offer coverage with out-of-pocket costs typically under $330.

For those without coverage, available financial assistance programs can make this technology accessible to people in publicly funded behavioral treatment centers and residential programs.

Finding Comprehensive Behavioral Health Treatment

Pharmacogenomic testing is one tool in a much larger picture of mental health care. Effective treatment for depression, anxiety, PTSD, bipolar disorder, or dual diagnosis also includes evidence-based therapies such as cognitive (CBT) and dialectical behavior therapy (DBT), trauma-focused therapy, and medication management by a trained psychiatrist.

Mental health treatment facilities are increasingly incorporating precision medicine tools like DNA-guided prescribing alongside these modalities to give patients in residential treatment centers and outpatient programs a more personalized path to recovery.
If you or a loved one struggles with depression, anxiety, addiction, or co-occurring disorders, comprehensive care starts with finding the right facility. Call 800-908-4823 (Sponsored) to speak with a specialist or browse our directory to find dual diagnosis treatment programs and mental health treatment facilities near you.

Author

Terri Beth Miller, PhD

Author, Award-Winning Post-Secondary Teacher

Read Bio

Terri Beth received her PhD in English literature from the University of Tennessee Knoxville and is an educator and disability studies scholar. For more than a decade, she has written extensively in the fields of mental health and addiction recovery and fiercely advocates for the destigmatization of mental illness.

Editor

Peter Lee, PhD

Read Bio

Peter W.Y. Lee is a writer and historian of American history during the Cold War. His primary focus is the relationship between youth and popular culture and its impact on U.S. society during the twentieth century. He has published widely on how the public has used popular culture as a mechanism to address political and social shifts throughout time